FDA grants Fast Track Designation for Ofirnoflast (HT-6184) in Lower-Risk MDS
“Receiving Fast Track designation is an important milestone for Halia and reflects the significant unmet need that remains for patients with lower-risk MDS,” said David J. Bearss, Ph.D., Chief Executive Officer of Halia Therapeutics. “The designation follows encouraging Phase 2 results demonstrating durable transfusion independence and multilineage hematologic improvement and provides an important opportunity to work closely with the FDA as we advance ofirnoflast toward pivotal development. Patients who no longer respond to erythropoiesis-stimulating agents or erythroid maturation agents often face limited options and a substantial burden from chronic anemia and transfusion dependence.”
Share:
More News
Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20
“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of
“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence
“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib